Clinical Trial Update: A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) [Phase 2]

View source ↗

Summary

A Phase 2 prospective, multi-centre trial evaluating redifferentiation therapy in patients with radioiodine-refractory thyroid cancer (I-FIRST study).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Cancer

Snippet

Sponsor: Olivia Newton-John Cancer Research Institute | Conditions: Thyroid Cancer | Phase 2 | Status: UNKNOWN